International, Peer Reviewed, Open Access Journal

Journal of Clinical Pharmacology and Therapeutics
(ISSN: 2766-8347)

Submit Manuscript

Journal of Clinical Pharmacology and Therapeutics

Journal of Clinical Pharmacology and Therapeutics is an open access peer reviewed journal which provides latest updates in treatments, advanced procedures, technologies associated within the field of Pharmacology and other related sub-divisions.

Journal Features

Open Access

All the articles will be published under Open Access model.

Peer Review

Our editorial team performs strict peer-review process.

Publication Ethics

The journal follows standard guidelines to maintain transparency.

Submit Manuscript

The journal accepts all original articles, reviews and more.

About the Journal

Journal of Clinical Pharmacology and Therapeutics provide reports on optimal clinical use of various drugs and effects in treatment of patients.

Open Access - Journal of Clinical Pharmacology and Therapeutics

Editorial Board

Sana Irfan Khan - Journal of Clinical Pharmacology and Therapeutics

Sana Irfan Khan

Volunteering as a peer reviewer for submitted manuscripts
United States

ÖMER ALKAN - Journal of Clinical Pharmacology and Therapeutics

ÖMER ALKAN

Associate professor in the department of econometrics
Turkey

Bruno Trimarco - Journal of Clinical Pharmacology and Therapeutics

Bruno Trimarco

Federico II University of Naples (www.unina.it)
Federico II University of Naples, Director of Division of Cardiology, Coronary care unit and Cat Lab Business or sector Medical

Italy

Athanasia Papazafiropoulou - Journal of Clinical Pharmacology and Therapeutics

Athanasia Papazafiropoulou

General Hospital of Piraeus “Tzaneio”, 1st Department of Internal Medicine
Greece

Articles

J Clin Pharmacol Ther. 2021;2(3):JCPT-02-1023 | Open Access

Overview of ABO-Blood Types and Mortality Outcome of COVID-19 Patients: An Observational Study in Bangladeshi Cohort

Tahmina Zahan, Morshed Nasir, Abdul Quddus Shohag, Rawshan Ara perveen, Sayma Parvin and Abdul Quddus Shohag

Background: The objective was to perceive the demographic characteristics, clinical symptoms, comorbidities, and biomarkers (hematological, inflammatory, hepatic, renal, and metabolic) of Intensive Care Unit admitted survivors and deceased patients with coronavirus and link with ABO system admitted to a tertiary level hospital in Dhaka, Bangladesh. Methods: It was a retrospective cohort, conducted in Holy Family Red Crescent Medical College Hospital, ... Read more

RESEARCH ARTICLE Updated Nov 24, 2021   PDF

J Clin Pharmacol Ther. 2021;2(3):JCPT-02-1022 | Open Access

Boosting Health Recovery by Food Supplements: The Case of ME/CFS versus Post-Covid-19 Syndrome

Frank Comhaire and Jan Pen

Background and objectives: Other than the direct impact of cardiopulmonary sequelae, COVID-19 disease may cause persistent signs and symptoms describes as post-COVID syndrome or long COVID. The clinical presentation and neuroimaging aspects of patients suffering from this condition are remarkably similar to those seen in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Inflammation, immune disorder and oxidative damage ... Read more

RESEARCH ARTICLE Updated Nov 10, 2021   PDF

J Clin Pharmacol Ther. 2021;2(3): JCPT-02-1021 | Open Access

A Sodium-Glucose Cotransporter-2 Inhibitor Modulates the Skin Hydration State in Type 2 Diabetes Patients: Post-Hoc Analysis of a Prospective, Open-Label Pilot Study

Yuji Tezuka, Osamu Sekine, Akiko Hirano, Yukako Hanada, Kayo Harada, Choka Azuma, Yukako Yamamoto, Jun Ito Kobayashi, Miki Washiyama, Masanori Iwanishi, Masao Kanamori, Akira Shimatsu and Atsunori Kashiwagi

We conducted a prospective open-label, short-term, and double-arm exploratory study to investigate changes in the skin hydration state in Japanese patients with Type 2 Diabetes Mellitus (T2DM) treated with either 50 mg ipragliflozin (a Sodium-Glucose Cotransporter-2 Inhibitor: SGLT2i) (n=8) or 50 mg sitagliptin (as a control) (n=6) 1×/day for 14 days. We performed a post-hoc analysis of reported clinical data to ... Read more

SHORT COMMUNICATION Updated Oct 27, 2021   PDF

J Clin Pharmacol Ther. 2021;2(3):JCPT-02-1020 | Open Access

Mutation in PIK3CD Associated with Immunodeficiency, Autoimmune Hemolytic Anemia and Splenomegaly

Nilgun Eroglu, Ömer Akcal, Metin Cil, Hatice Mutlu Albayrak and Dilek Karagoz

Activated PI3K-Delta Syndrome (APDS) is an immunodeficiency caused by gain-of-function mutations in PIK3CD. This disease exhibits complex immune phenotypes including increased IgM, recurrent infection, and impaired vaccine responses. Patients with APDS also experience other complications including lymphoid hyperplasia, autoimmunity, increased susceptibility to herpes viruses, especially Epstein-Barr virus and cytomegalovirus, and an increased incidence of B-cell lymphoma. In this ... Read more

CASE REPORT Updated Oct 07, 2021   PDF

J Clin Pharmacol Ther. 2021;2(2):JCPT-02-1019 | Open Access

Atypical Case of Autosomal Recessive Agammaglobulinemia Presenting with Mild Hypogammaglobulinemia and Follow Up Findings

Omer Akcal, Ilke Taskirdi, Selime Ozen, Idil Akay Haci, Semiha Bahçeci Erdem, Sait Karaman, Nesrin Gulez and Ferah Genel

Autosomal recessive Agammaglobulinemia (ARA) is an uncommon type of congenital Agammaglobulinemia characterized by the absence of any of the molecules that constitutes the pre-B cell receptor complex at the B lymphocyte developmental stages. ARA is defined by profound hypogammaglobulinemia of all immunoglobulin isotypes and absence of circulating B lymphocytes. Herein, we report an atypical case of ARA with λ5/14.1 deficiency ... Read more

CASE REPORT Updated Sep 24, 2021   PDF